Why the study?
Saudi patients experience CVD events nearly a decade earlier than Western counterparts, and traditional risk assessment tools have limitations for refining risk stratification and primary prevention in younger and asymptomatic individuals.
Does systematic screening for subclinical atherosclerosis using non-invasive imaging improve risk stratification and primary prevention in individuals aged 35 years or older with borderline or intermediate 10-year ASCVD risk?
Does systematic screening for subclinical atherosclerosis using non-invasive imaging improve risk stratification and primary prevention in individuals aged 35 years or older with borderline or intermediate 10-year ASCVD risk?
The Saudi Heart Association recommends systematic screening for subclinical atherosclerosis using non-invasive imaging in individuals aged 35 years or older with borderline or intermediate ASCVD risk to guide primary prevention.
Answers are grounded in this paper and cite their sources.
May enhance risk stratification in intermediate-risk Saudis; leaves open need for prospective outcome validation.
Background: Atherosclerosis is the leading underlying cause of cardiovascular disease (CVD), which remains the primary cause of mortality in Saudi Arabia. Saudi patients experience CVD events nearly a decade earlier than their Western counterparts. Given the limitations of traditional risk assessment tools, there is a growing need to detect subclinical atherosclerosis to refine risk stratification and improve primary prevention strategies, particularly in younger and asymptomatic individuals. Methods: The Saudi Heart Association (SHA) developed this position statement through a structured, multistep process that included a comprehensive literature review and two expert panel meetings. Recommendations were formulated based on current evidence, expert consensus, and consideration of population-specific characteristics and healthcare infrastructure in Saudi Arabia. The final recommendations were reviewed by the expert panel to ensure scientific accuracy and relevance to local practice. Results and conclusions: The SHA recommends systematic screening for subclinical atherosclerosis in individuals aged 35 years or older with borderline or intermediate 10-year ASCVD risk (5–20%). Subclinical atherosclerosis can be assessed using validated non-invasive imaging modalities: coronary artery calcium (CAC) scoring, coronary computed tomography angiography (CCTA), carotid ultrasound, or ankle-brachial index (ABI). CAC scoring is the most validated modality, especially in individuals aged ≥40 years, while CCTA offers the advantage of detecting both calcified and non-calcified plaques. Carotid ultrasound can be advantageous in younger adults, and ABI is useful in older adults. Management should be tailored to disease burden: lifestyle modification is advised for individuals with minimal disease, while moderate- to high-intensity statin therapy is recommended in those with mild or moderate to severe subclinical disease. These recommendations aim to support evidence-based integration of subclinical atherosclerosis screening into routine clinical practice, facilitating earlier interventions and reducing the burden of cardiovascular disease in Saudi Arabia.
No takes yet. Share an insight, caveat, or question.
Alhabeeb et al. (2026) studied this question. The Saudi Heart Association recommends systematic screening for subclinical atherosclerosis in individuals aged 35+ with 10-year ASCVD risk of 5–20%.
Synapse has enriched 10 related papers. Consider them for comparative context: